“I'm very pleased with our strong full-year financial results. We lifted both our sales growth and our EBIT margin to the upper end of our guidance range. With our healthy growth performance in all business areas and in all regions during the past financial year, we have consolidated our position as a global market leader,” says Coloplast’s CEO Lars Rasmussen.
Sales growth by business area was as follows: Ostomy Care 7%, Continence Care 7%, Urology Care 9% and Wound & Skin Care 5%. Revenue increased by 5% in Europe, by 9% in other developed markets and by 14% in other markets.
“These are excellent results. We grew our business by 7% overall in a market that is growing by 4–5%. We're beginning to see the results of the investments in growth we announced in 2012, and we expect this strong growth to continue into next year,” Lars Rasmussen adds.
For the 2013/2014 financial year, Coloplast projects revenue growth of about 7% and an EBIT margin of around 33%, both at constant exchange rates and in DKK.
Distributor agreement for the Wound Care business based on innovative technology
Together with the release of the full-year financial report, Coloplast is announcing a new distributor agreement with the US-based medtech company Devon Medical International.
The agreement gives Coloplast exclusive rights to distribute Devon's already approved product portfolio for Negative Pressure Wound Therapy (NPWT) in the EU, Brazil, China and other markets.
“Our Wound Care business has grown for three straight quarters, and we've now completed the turnaround we initiated a few years back. The deal with Devon is a natural next step in achieving our ambition for sustained growth in this business area,” says Lars Rasmussen.
For further information, click here to read the Full Year Financial Report for 2012/2013.
The Coloplast Annual Report for 2012/13 will be released later today. For more information, go to http://www.coloplast.dk/omcoloplast/investorrelations/arsrapporter/
Also later today, Coloplast will release its Corporate Responsibility Report for 2012/13. For more information, go to http://www.coloplast.com/about/responsibility/
PRESS CONTACT
Ulla Lundhus
Head of Media and Positioning
+45 4911 1929
dkul@coloplast.com
Simon Mehl Augustesen
Media Relations Manager
+45 4911 3488
dksia@coloplast.com
INVESTOR RELATIONS
Ian Christensen
Vice President, Investor Relations
+45 4911 1301
dkisec@coloplast.com
